Acquisition of Infant Nutritional businesses from Nestle - Voluntary Announcement ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 ("Aspen Holdings" or "the Company") ACQUISITION OF INFANT NUTRITIONAL (“IN”) BUSINESSES FROM NESTLÉ – VOLUNTARY ANNOUNCEMENT Further to the announcement released on 18 April 2013 wherein shareholders of Aspen Holdings were advised of a transaction in terms whereof Aspen Group Companies (“Aspen”) would acquire the IN businesses conducted by Nestlé and Pfizer which distribute a portfolio of IN products in Australia and certain Southern African territories, shareholders of Aspen Holdings are advised that additional agreements have now been concluded with Nestlé S.A. in respect of the acquisition of certain license rights to intellectual property, net assets (including an IN production facility located in Vallejo, Mexico) and shares in the IN businesses presently conducted by Nestlé and Pfizer in Latin America, predominantly Mexico, Venezuela, Colombia, Ecuador, Chile, Peru, Central America and the Caribbean (collectively, “the Transaction”). The Transaction includes all age stages (infants, toddlers and early childhood) and consists of premium and specialty ranges supported by strong umbrella brands including S26 Gold® and SMA®. The revenue for the IN businesses amounted to USD 187 million in 2012. The Transaction is subject to certain antitrust conditions. The nature of the Transaction and the assets relating thereto are set out below: - Aspen will have the exclusive right of use of the Nestlé (previously Pfizer) S26® and SMA® IN product trademarks for a period of 10 years(“licensed products”)in those countries in South and Central America in which the brands are currently sold; - Aspen will also have the right to co-brand the licensed products over the initial 10 year period and to transition these products to Aspen branded products over this period; - For a further 10 year period, commencing after expiration of the initial 10 year exclusive licence period, Nestlé will be precluded from commercialising the licensed products (so-called “10 year black out period”), effectively providing Aspen with a 20 year period to establish equivalent Aspen branded IN products; - Aspen will have a perpetual licence to the IN technology, technical know-how and formulations existing at the effective date plus access to an agreed licensed product pipeline together with related technology developments for a period of 5 years from the effective date; - There will be a transfer of the ownership in the operating businesses from Nestlé to Aspen and this will include the transfer of the employees within those businesses and ownership of the IN production facility located in Vallejo, Mexico; and - Aspen will be provided with transitional service arrangements by Nestlé and Pfizer to assist Aspen in fully integrating the IN businesses into the Aspen business. The Transaction is strategically significant as it enhances Aspen’s platform to become a global player in the IN market in the medium term. Durban 7 August 2013 Sponsor Investec Bank Limited Underwriters Bank of America, N.A. The Standard Bank of South Africa Limited Mandated Lead Arrangers and Bookrunners Banc of America Securities Limited The Standard Bank of South Africa Limited Date: 07/08/2013 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.